Trials / Completed
CompletedNCT01181102
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS E-3 Trial)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 716 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 84 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | edoxaban | |
| DRUG | enoxaparin sodium |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2009-09-01
- Completion
- 2010-02-01
- First posted
- 2010-08-13
- Last updated
- 2019-03-05
- Results posted
- 2015-02-19
Locations
3 sites across 2 countries: Japan, Taiwan
Source: ClinicalTrials.gov record NCT01181102. Inclusion in this directory is not an endorsement.